Zobrazeno 1 - 7
of 7
pro vyhledávání: '"M. B. Jameson"'
Autor:
M. C. L. Phillips, J. Leyden, E. J. McManus, D. G. Lowyim, F. Ziad, B. G. Moon, N. A. B. Haji Mohd Yasin, A. Tan, Z. Thotathil, M. B. Jameson
Publikováno v:
Journal of Oncology. 2022:1-10
Background. Glioblastoma multiforme (GBM) may be susceptible to metabolic strategies such as fasting and ketogenic diets, which lower blood glucose and elevate ketones. Combining these two strategies may be an ideal approach for sustaining a potentia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae302557daef9ca3066eff0cee843fef
https://doi.org/10.1155/2022/4496734
https://doi.org/10.1155/2022/4496734
Publikováno v:
Journal of the Pediatric Infectious Diseases Society
Chronic Granulomatous Disease is one of the classic primary immunodeficiencies of childhood. While the incidence and severity of bacterial and fungal infections have been greatly reduced in this patient population, much remains to be learned about th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c86d436a35dd1ce657d8b938fe877389
http://europepmc.org/articles/PMC5946813
http://europepmc.org/articles/PMC5946813
Autor:
J. Thomson, M. B. Jameson, D. H. Gray, S. G. Allan, V. J. Harvey, B. D. Evans, G. Humm, G. V. Forgeson, Paul Thompson
Publikováno v:
Australian and New Zealand journal of medicine. 25(3)
Background : Adjuvant chemotherapy significantly improves survival of patients with non-metastatic osteosarcoma but most of the data come from trials conducted in major international cancer centres. Aim : To review the efficacy and toxicity of an adj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86ee304046bf6a2c784b38efd4d27c7e
https://pubmed.ncbi.nlm.nih.gov/8744624
https://pubmed.ncbi.nlm.nih.gov/8744624
Autor:
S. Deva, M. B. Jameson
Publikováno v:
Journal of Clinical Oncology. 27:e15085-e15085
e15085 Background: H2RAs have induced regression in a number of malignancies. The mechanisms that may contribute to this effect include inhibition of T-suppressor lymphocytes, increased tumor infiltrating lymphocytes and blockade of histamine-induced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b4b14bd464dc5f75f9afab62a0d845de
https://doi.org/10.1200/jco.2009.27.15_suppl.e15085
https://doi.org/10.1200/jco.2009.27.15_suppl.e15085
Autor:
M. B. Jameson, M. J. McKeage
Publikováno v:
Journal of Clinical Oncology. 26:8072-8072
8072 Background: DMXAA (ASA404) is a tumor vascular disrupting agent recently evaluated in phase II trials in NSCLC. A randomized trial compared DMXAA 1,200 mg/m2 plus carboplatin and paclitaxel (CP) with CP alone (median survival 14.0 vs 8.8 months)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::43a81e7f9f5fbbbee122dcf356411203
https://doi.org/10.1200/jco.2008.26.15_suppl.8072
https://doi.org/10.1200/jco.2008.26.15_suppl.8072
Autor:
B. R. Penfold, M. B. Jameson
Publikováno v:
Journal of the Chemical Society (Resumed). :528
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::162fd85cb4063dad8a1e20ed2da2a1d4
https://doi.org/10.1039/jr9650000528
https://doi.org/10.1039/jr9650000528
Autor:
Hari Dass P; Waikato District Health Board, Hamilton, New Zealand., B Jameson M; Waikato District Health Board, Hamilton, New Zealand.; Waikato Clinical Campus, University of Auckland, Hamilton, New Zealand.
Publikováno v:
Internal medicine journal [Intern Med J] 2020 Nov; Vol. 50 (11), pp. 1344-1349.